Clinical trial
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis…
NCT01997229 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT01997229 |
|---|---|
| Title | Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Refractory Generalized Myasthenia Gravis |
| Intervention type | Biological, Drug |
| Interventions | Eculizumab, Placebo |
| Enrollment | 125 |
| Start date | Dec 1, 2013 |
| Primary completion | Feb 1, 2016 |
| Completion | Jun 1, 2016 |
| First posted | Nov 28, 2013 |
| Last update posted | Jul 16, 2019 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Hungary and 9 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: